No fast way to Covid glory for Adagio
The company’s short history, a cautionary tale about investing in the hype around all things Covid, reaches the point of show and tell.
Pfizer waits for paediatric Comirnaty data to mature
A look at the past week’s Covid winners and losers finds Pfizer, unusually, among the latter.
The sellside’s most controversial products
Drugs prompting the most divergent opinions on outlook include Pfizer and Vir’s Covid-19 offerings and Biogen’s Aduhelm.
Brii gets a Covid-19 antibody boost
But is there room for another antibody, given lacklustre sales and Regeneron’s dominance?